Market Currents
For what it's worth, Goldman analyst Jami Rubin thinks Johnson & Johnson (JNJ) would be more...
-
Thursday, May 31, 2012, 5:48 PM ETFor what it's worth, Goldman analyst Jami Rubin thinks Johnson & Johnson (JNJ) would be more valuable if it split up than as one conglomerate: "On an operational basis, we believe that JNJ’s businesses, separated as independent companies, would benefit from being more focused and potentially achieve peer group performance levels or better."
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 7 comments:
Would that be the same analyst who talks about the "expected synergies" and "cost savings" whenever he discusses a potential merger?
I guess Goldman Sachs doesn't make any money if successful companies simply keep doing, y'know, what they're good at, without hiring advisors to alternately merge and split up.
Long: JNJ